289 related articles for article (PubMed ID: 31455248)
1. Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials.
Zhang Z; Yang Y; Jiang SM; Li WG
BMC Nephrol; 2019 Aug; 20(1):333. PubMed ID: 31455248
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature.
Zheng J; Gong X; Wu Z
Niger J Clin Pract; 2020 Apr; 23(4):437-449. PubMed ID: 32246648
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive agents for treating IgA nephropathy.
Samuels JA; Strippoli GF; Craig JC; Schena FP; Molony DA
Cochrane Database Syst Rev; 2003; (4):CD003965. PubMed ID: 14584001
[TBL] [Abstract][Full Text] [Related]
5. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of glucocorticoids for patients with IgA nephropathy: a meta-analysis.
Qian G; Zhang X; Xu W; Zou H; Li Y
Int Urol Nephrol; 2019 May; 51(5):859-868. PubMed ID: 30843135
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.
Song YH; Cai GY; Xiao YF; Wang YP; Yuan BS; Xia YY; Wang SY; Chen P; Liu SW; Chen XM
BMC Nephrol; 2017 Feb; 18(1):61. PubMed ID: 28193247
[TBL] [Abstract][Full Text] [Related]
8. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
Nagy J; Sági B; Máté J; Vas T; Kovács T
Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis.
Liu T; Wang Y; Mao H; Yang L; Zhan Y
Medicine (Baltimore); 2021 Feb; 100(8):e24541. PubMed ID: 33663060
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?
Lin Y; Jia J; Guo Y; He D; Zhang Y; Wang F; Yan T; Liu Y; Lin S
Am J Nephrol; 2018; 47(6):385-394. PubMed ID: 29874651
[TBL] [Abstract][Full Text] [Related]
11. Steroid therapy in children with IgA nephropathy.
Cambier A; Boyer O; Deschenes G; Gleeson J; Couderc A; Hogan J; Robert T
Pediatr Nephrol; 2020 Mar; 35(3):359-366. PubMed ID: 30778826
[TBL] [Abstract][Full Text] [Related]
12. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
Eitner F; Ackermann D; Hilgers RD; Floege J
J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials.
Samuels JA; Strippoli GF; Craig JC; Schena FP; Molony DA
Nephrology (Carlton); 2004 Aug; 9(4):177-85. PubMed ID: 15363047
[TBL] [Abstract][Full Text] [Related]
14. Non-immunosuppressive treatment for IgA nephropathy.
Reid S; Cawthon PM; Craig JC; Samuels JA; Molony DA; Strippoli GF
Cochrane Database Syst Rev; 2011 Mar; (3):CD003962. PubMed ID: 21412884
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials.
Cheng J; Zhang X; Zhang W; He Q; Tao X; Chen J
Am J Nephrol; 2009; 30(4):315-22. PubMed ID: 19546530
[TBL] [Abstract][Full Text] [Related]
16. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials.
Cheng J; Zhang W; Zhang XH; He Q; Tao XJ; Chen JH
Int J Clin Pract; 2009 Jun; 63(6):880-8. PubMed ID: 19490198
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis.
Tan J; Dong L; Ye D; Tang Y; Hu T; Zhong Z; Tarun P; Xu Y; Qin W
Sci Rep; 2020 Apr; 10(1):6062. PubMed ID: 32269271
[TBL] [Abstract][Full Text] [Related]
18. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
[TBL] [Abstract][Full Text] [Related]
19. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up.
Tian L; Shao X; Xie Y; Wang L; Wang Q; Che X; Ni Z; Mou S
Expert Opin Pharmacother; 2015 Jun; 16(8):1137-47. PubMed ID: 25892092
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
